Skip to main content
. Author manuscript; available in PMC: 2024 Apr 4.
Published in final edited form as: Cancer Immunol Res. 2023 Oct 4;11(10):1414–1431. doi: 10.1158/2326-6066.CIR-23-0092

Figure 1. Ncoa2 deficient mice are defective in anti-tumor immune responses.

Figure 1.

WT and Ncoa2fl/fl/CD4Cre mice were subcutaneously implanted with 3 x 106 MC38-ovalbumin (Ova) cancer cells and euthanized on day 19 post-implantation for assessment (n=9-10, 2 independent experiments). (A-B) Tumor volume (A), size (B, left panel), and weight (B, right panel) of indicated mice. (B) Tumor size and weight were measured at day 19 post-engraftment when mice were eventually euthanized. (C) Flow cytometric analysis of the percentage of CD8+ T cells among CD45+ tumor-infiltrating lymphocytes (TILs) from indicated mice. (D) Representative flow cytometric analysis and percentage of H-2K(b) Ova257-264 tetramer+ (Ova-Tetra+) among tumor infiltrated CD8+ T cells from indicated mice (E-H) Representative flow cytometric analysis (left panels) and percentage (right panel) of IFN-γ+ (E), IL-10+ (F), PD-1+Tim3+ (G, top panels), PD-1+Lag3+ (G, bottom panels), and TCF-1+ (H) cells among tumor-infiltrating CD8+/Ova-Tetra+ T cells from indicated mice. (I-J) Flow cytometric analysis of the percentage of CD4+/CD45+ (I) and Fopx3+/CD4+ in tumors shown in (A). Data are shown as mean ± SEM. **P<0.01; ***P<0.001 (two-tailed unpaired Student’s t-test).